Clinical Significance of BPI-ANCA in Patients with Cystic Fibrosis: a Single Center Prospective Study

Overview

Journal Sci Rep

Specialty Science

Date 2023 Oct 24

PMID 37875496

Authors

Kenneth Iwuji

Adaobi Kanu

Stephanie Stroever

Kenneth Nugent

Abdul Hamood

Chris Scott

Stephany Navarro

Affiliations

Soon will be listed here.

Abstract

Recurrent pulmonary exacerbation due to infection and inflammation remain the major cause of mortality and morbidity in patients with cystic fibrosis (CF). Increased levels of BPI-ANCA have been linked to Pseudomonas colonization and pulmonary exacerbations in patients with CF. The majority of these studies were done in Europe, and it is unclear whether similar findings are true in CF patients who lives in United States. In our single center study of 47 patients with CF, the prevalence of BPI-ANCA was 19% at baseline and 15% at annual follow-up visit. Overall, there were no statistical differences noted in FEV1 and frequency of pulmonary exacerbations in CF patients who were positive for BPI-ANCA compared to those who were negative for BPI-ANCA. The role of BPI-ANCA in patients with CF still remains unclear.

References

Hovold G, Lindberg U, Ljungberg J, Shannon O, Pahlman L . BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization. Respir Med. 2020; 170:105994. DOI: 10.1016/j.rmed.2020.105994. View

Goetz D, Savant A . Review of CFTR modulators 2020. Pediatr Pulmonol. 2021; 56(12):3595-3606. DOI: 10.1002/ppul.25627. View

Lindberg U, Carlsson M, Lofdahl C, Segelmark M . BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study. Clin Dev Immunol. 2013; 2012:370107. PMC: 3546553. DOI: 10.1155/2012/370107. View

Tian Y, Zeng T, Tan L, Wu Y, Yu J, Huang J . Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization. J Clin Lab Anal. 2019; 33(6):e22908. PMC: 6642326. DOI: 10.1002/jcla.22908. View

Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J . Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin. Rheumatol Int. 2000; 19(4):129-36. DOI: 10.1007/s002960050116. View

Habib A, Kajbafzadeh M, Desai S, Yang C, Skolnik K, Quon B . A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep. 2019; 9(1):7234. PMC: 6510767. DOI: 10.1038/s41598-019-43652-2. View

Lindberg U, Carlsson M, Hellmark T, Segelmark M . BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients. J Immunol Res. 2015; 2015:947934. PMC: 4529961. DOI: 10.1155/2015/947934. View

Graham B, Steenbruggen I, Miller M, Barjaktarevic I, Cooper B, Hall G . Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200(8):e70-e88. PMC: 6794117. DOI: 10.1164/rccm.201908-1590ST. View

Carlsson M, Eriksson L, Pressler T, Kornfalt R, Mared L, Meyer P . Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. J Cyst Fibros. 2006; 6(3):228-33. DOI: 10.1016/j.jcf.2006.10.005. View

10.

Iwuji K, Larumbe-Zabala E, Bijlani S, Nugent K, Kanu A, Manning E . Prevalence of Bactericidal/Permeability-Increasing Protein Autoantibodies in Cystic Fibrosis Patients: Systematic Review and Meta-Analysis. Pediatr Allergy Immunol Pulmonol. 2019; 32(2):45-51. PMC: 6733050. DOI: 10.1089/ped.2018.0970. View

11.

McQuillan K, Gargoum F, Murphy M, McElvaney O, McElvaney N, Reeves E . Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis. Front Pharmacol. 2020; 11:1098. PMC: 7379883. DOI: 10.3389/fphar.2020.01098. View